Business Description
Larimar Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US5171251003
Description
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 37.99 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | -0.07 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 35.9 | |||||
| 3-Year EPS without NRI Growth Rate | 38.3 | |||||
| 3-Year FCF Growth Rate | 40.1 | |||||
| 3-Year Book Growth Rate | -31.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -35.52 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 9.08 | |||||
| 9-Day RSI | 17.18 | |||||
| 14-Day RSI | 24 | |||||
| 6-1 Month Momentum % | -15.5 | |||||
| 12-1 Month Momentum % | 43.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 13.1 | |||||
| Quick Ratio | 13.1 | |||||
| Cash Ratio | 12.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -41.9 | |||||
| Shareholder Yield % | -67.17 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -39.73 | |||||
| ROA % | -35.81 | |||||
| ROIC % | -825.62 | |||||
| ROC (Joel Greenblatt) % | -1977.77 | |||||
| ROCE % | -44.01 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.27 | |||||
| Price-to-Tangible-Book | 1.27 | |||||
| EV-to-EBIT | -0.79 | |||||
| EV-to-EBITDA | -0.8 | |||||
| EV-to-FCF | -0.93 | |||||
| Price-to-Net-Current-Asset-Value | 1.25 | |||||
| Price-to-Net-Cash | 1.32 | |||||
| Earnings Yield (Greenblatt) % | -126.58 | |||||
| FCF Yield % | -23.07 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LRMR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Larimar Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.14 | ||
| Beta | 0.58 | ||
| Volatility % | 122.41 | ||
| 14-Day RSI | 24 | ||
| 14-Day ATR ($) | 0.590618 | ||
| 20-Day SMA ($) | 5.5565 | ||
| 12-1 Month Momentum % | 43.93 | ||
| 52-Week Range ($) | 3.01 - 13.68 | ||
| Shares Outstanding (Mil) | 63.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Larimar Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Larimar Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Larimar Therapeutics Inc Frequently Asked Questions
What is Larimar Therapeutics Inc(LRMR)'s stock price today?
The current price of LRMR is $3.78. The 52 week high of LRMR is $13.68 and 52 week low is $3.01.
When is next earnings date of Larimar Therapeutics Inc(LRMR)?
The next earnings date of Larimar Therapeutics Inc(LRMR) is 2025-03-14 Est..
Does Larimar Therapeutics Inc(LRMR) pay dividends? If so, how much?
Larimar Therapeutics Inc(LRMR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers